Article Text

Download PDFPDF
155 Patient support program for RRMS patients treated with DMF
  1. Joana Monterroso1,
  2. Janette Curlis2,
  3. Leontia Gribben2
  1. 1Biogen, Maidenhead, UK
  2. 2IQVIA, Reading, Berkshire


Introduction In the UK, the number of patients with relapsing-remitting multiple sclerosis (RRMS) far exceeds the capacity of MS specialist nurses (MSSNs).

Methods Biogen and IQVIA developed a remote, nurse-led, script-based telephone line to provide educational assistance and support treatment adherence among adult RRMS patients receiving delayed-release dimethyl fumarate (DMF). In the year following DMF initiation, 8 calls are scheduled over the first 3 months, followed by 3 quarterly calls. An optional online satisfaction survey was added to the program in July 2017.

Results Based on summarized call data from March 2015 through November 2018, 1204 patients were enrolled from 136 UK hospitals, with a mean (median, range) of 8.5 (2, 1–168) patients/hospital. An average of 10.8 calls/patient were received. Across 11 scheduled calls, average time/call was 13 minutes. Over this period, cumulative reported DMF discontinuation among enrolled patients was 12.7%. Between July 2017 and September 2018, 76% of survey responders treated for ≥1 year (n=78) would recommend the service (score ≥5, scale: 1 [not at all] to 7 [extremely likely]).

Conclusion This program has been widely used and positively received across the UK by DMF-treated patients and should help reduce the burden on MSSNs.

Support: Biogen. Disclosures to be presented on poster.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.